SCHEMBL2314604

SCHEMBL2314604

CCCCCCC1=C2C=CC(=N2)C(CCCCCC)=C2C=CC(=N2)C(c2ccc(C(=O)O)cc2)=C2C=CC(=N2)C(c2ccc(C(=O)O)cc2)=C2C=CC1=N2

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RARB P10826 12/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ RARA P10276 1/20 0.51
▸ MAPT P10636 1/20 0.51
▸ MTOR P42345 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ NPC1 O15118 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ PTPN11 Q06124 1/20 0.41
▸ TP53 P04637 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ PLA2G4B P0C869 1/20 0.39
▸ CSNK2A2 P19784 1/20 0.39
▸ CSNK2A1 P68400 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2310945 1.00 RARB (0.51) RARBMEN1ALDH1A1RARAMAPT
SCHEMBL2319620 0.87 MAPT (0.43) RARBMEN1ALDH1A1RARAMAPT
SCHEMBL2318543 0.87 MAPT (0.43) RARBMEN1ALDH1A1RARAMAPT
SCHEMBL2342869 0.87 MAPT (0.43) RARBMEN1ALDH1A1RARAMAPT
SCHEMBL8198894 0.84 ESR1 (0.41) MEN1ALDH1A1MAPTKMT2ANPC1
SCHEMBL10614683 0.81 RAB9A (0.36) MEN1ALDH1A1MAPTKMT2ANPC1
SCHEMBL17681582 0.81 CASP3 (0.42) ALDH1A1MAPTNPC1RAB9A
SCHEMBL17681578 0.81 CASP3 (0.42) ALDH1A1MAPTNPC1RAB9A
SCHEMBL3475755 0.80 TSHR (0.44) ALDH1A1NPC1RAB9ATP53TSHR
SCHEMBL2317204 0.79 RARB (0.38) RARBMEN1ALDH1A1RARAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9315510-B2 Method and application of unsymmetrically meso-substituted porphyrins and chlorins for PDT BIOLITEC PHARMA MARKETING LTD (MY) 2016-04-19 — — US claimed
EP-3459955-B1 NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT BIOLITEC UNTERNEHMENSBERATUNGS II AG (AT) 2022-11-02 — — EP disclosed
EP-3459955-A1 NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT biolitec Unternehmensbeteiligungs II AG (AT) 2019-03-27 — — EP disclosed
EP-2350058-B1 NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) 2018-10-24 — — EP disclosed
US-9315510-B2 Method and application of unsymmetrically meso-substituted porphyrins and chlorins for PDT BIOLITEC PHARMA MARKETING LTD (MY) 2016-04-19 — — US disclosed
US-20110206613-A1 METHOD AND APPLICATION OF UNSYMMETRICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) 2011-08-25 — — US disclosed
EP-2350058-A2 NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT CeramOptec GmbH (DE) 2011-08-03 — — EP disclosed
WO-2010033678-A2 NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT CERAMOPTEC INDUSTRIES, INC. (US) 2010-03-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110206613-A1 METHOD AND APPLICATION OF UNSYMMETRICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT PTDSS2, PTDSS1, DLST RARB 1107/4885MEN1 827/4885ALDH1A1 2916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback